ELEV — Elevation Oncology Share News
0.000.00%
Last trade - 00:00Brief: CSPC Pharmaceutical Announces Exclusive License Agreement For Sysa1801 With Elevation Oncology, Inc.
Brief: Elevation Oncology Files For Mixed Shelf Of Up To $250 Million
Brief: Venbio Global Strategic Fund III Reports 8.03% Stake In Elevation Oncology Inc
Pains and gains for cancer drugmakers ahead of industry meet
Merus on track for best day on promising cancer drug trial data
Elevation Oncology rises on promising data on cancer drug
Brief: Elevation Oncology To Present Initial Seribantumab Proof-Of-Concept Data From Phase 2 Crestone Study In Patients With Tumors Harboring Nrg1 Fusions At Asco 2022
Elevation Oncology jumps on FDA fast track tag for cancer antibody drug
Brief: Elevation Oncology Announces FDA Fast Track Designation Granted To Seribantumab For Tumor-Agnostic Treatment Of Solid Tumors Harboring NRG1 Gene Fusions
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:11 PM
U.S. RESEARCH ROUNDUP- Black Knight, Dish Network, Whirlpool
Brief: Elevation Oncology Reports First Quarter 2022 Financial Results
U.S. STOCKS ON THE MOVE-Tesla Inc, LianBio, Intel Corp
U.S. RESEARCH ROUNDUP- Cara Therapeutics, DT Midstream, Fulcrum Therapeutics
Brief: Elevation Oncology Reports Fourth Quarter And Full Year 2021 Financial Results
NASDAQ RESUMED AT 10:05 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:55 AM
Brief: Elevation Oncology Highlights 2021 Achievements And Outlines Expected 2022 Milestones
U.S. RESEARCH ROUNDUP-American Woodmark, Faraday Future Intelligent Electric, Faraday Future Intelligent Electric,